Digital twins for multiple sclerosis

I Voigt, H Inojosa, A Dillenseger, R Haase… - Frontiers in …, 2021‏ - frontiersin.org
An individualized innovative disease management is of great importance for people with
multiple sclerosis (pwMS) to cope with the complexity of this chronic, multidimensional …

Clinical course of multiple sclerosis

S Klineova, FD Lublin - Cold Spring …, 2018‏ - perspectivesinmedicine.cshlp.org
The 1996 originally established multiple sclerosis (MS) subtypes, based solely on clinical
impression and consensus, were revised in 2013 to review potential imaging and biological …

How patients with multiple sclerosis acquire disability

FD Lublin, DA Häring, H Ganjgahi, A Ocampo… - Brain, 2022‏ - academic.oup.com
Patients with multiple sclerosis acquire disability either through relapse-associated
worsening (RAW) or progression independent of relapse activity (PIRA). This study …

Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis

A Cagol, S Schaedelin, M Barakovic, P Benkert… - JAMA …, 2022‏ - jamanetwork.com
Importance The mechanisms driving neurodegeneration and brain atrophy in relapsing
multiple sclerosis (RMS) are not completely understood. Objective To determine whether …

Silent progression in disease activity–free relapsing multiple sclerosis

University of California, San Francisco MS … - Annals of …, 2019‏ - Wiley Online Library
Objective Rates of worsening and evolution to secondary progressive multiple sclerosis
(MS) may be substantially lower in actively treated patients compared to natural history …

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

J Correale, MI Gaitán, MC Ysrraelit, MP Fiol - Brain, 2017‏ - academic.oup.com
During the past decades, better understanding of relapsing-remitting multiple sclerosis
disease mechanisms have led to the development of several disease-modifying therapies …

[HTML][HTML] Brain health: time matters in multiple sclerosis

G Giovannoni, H Butzkueven, S Dhib-Jalbut… - Multiple sclerosis and …, 2016‏ - Elsevier
Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

Long‐term evolution of multiple sclerosis disability in the treatment era

University of California, San Francisco MS … - Annals of …, 2016‏ - Wiley Online Library
Objective To characterize the accrual of long‐term disability in a cohort of actively treated
multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance …

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies

DM Wingerchuk, JL Carter - Mayo Clinic Proceedings, 2014‏ - Elsevier
Multiple sclerosis (MS) is a chronic inflammatory demyelinating central nervous system
disease that typically strikes young adults, especially women. The pathobiology of MS …

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

V Brinkmann, A Billich, T Baumruker… - Nature reviews Drug …, 2010‏ - nature.com
The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory
drug, has opened up new approaches to the treatment of multiple sclerosis, the most …